Convalescent plasma donors show enhanced cross‐reactive neutralizing antibody response to antigenic variants of SARS‐CoV‐2 following immunization. Issue 7 (2nd June 2022)
- Record Type:
- Journal Article
- Title:
- Convalescent plasma donors show enhanced cross‐reactive neutralizing antibody response to antigenic variants of SARS‐CoV‐2 following immunization. Issue 7 (2nd June 2022)
- Main Title:
- Convalescent plasma donors show enhanced cross‐reactive neutralizing antibody response to antigenic variants of SARS‐CoV‐2 following immunization
- Authors:
- Harvala, Heli
Nguyen, Dung
Simmonds, Peter
Lamikanra, Abigail A.
Tsang, Hoi Pat
Otter, Ashley
Maes, Piet
Webster, Mhairi
Clarkson, Adam
Kaloyirou, Fotini
Hopkins, Valerie
Laidlaw, Stephen M.
Carroll, Miles
Mora, Ana
Griffiths, Alexandra
MacLennan, Sheila
Estcourt, Lise
Roberts, David J. - Abstract:
- Abstract: Background: The therapeutic benefit of convalescent plasma (CP) therapy to treat COVID‐19 may derive from neutralizing antibodies (nAbs) to SARS‐CoV‐2. To investigate the effects of antigenic variation on neutralization potency of CP, we compared nAb titers against prototype and recently emerging strains of SARS‐CoV‐2, including Delta and Omicron, in CP donors previously infected with SARS‐CoV‐2 before and after immunization. Methods and Materials: Samples were assayed from previously SARS‐CoV‐2 infected donors before ( n = 17) and after one ( n = 43) or two ( n = 71) doses of Astra‐Zeneca or Pfizer vaccinations. Ab titers against Wuhan/wild type (WT), Alpha, Beta, and Delta SARS‐CoV‐2 strains were determined by live virus microneutralization assay while titers to Omicron used a focus reduction neutralization test. Anti‐spike antibody was assayed by Elecsys anti‐SARS‐CoV‐2 quantitative spike assay (Roche). Results: Unvaccinated donors showed a geometric mean titer (GMT) of 148 against WT, 80 against Alpha but mostly failed to neutralize Beta, Delta, and Omicron strains. Contrastingly, high GMTs were observed in vaccinated donors against all SARS‐CoV‐2 strains after one vaccine dose (WT:703; Alpha:692; Beta:187; Delta:215; Omicron:434). By ROC analysis, reactivity in the Roche quantitative Elecsys spike assay of 20, 000 U/mL was highly predictive of donations with nAb titers of ≥1:640 against Delta (90% sensitivity; 97% specificity) and ≥1:320 against OmicronAbstract: Background: The therapeutic benefit of convalescent plasma (CP) therapy to treat COVID‐19 may derive from neutralizing antibodies (nAbs) to SARS‐CoV‐2. To investigate the effects of antigenic variation on neutralization potency of CP, we compared nAb titers against prototype and recently emerging strains of SARS‐CoV‐2, including Delta and Omicron, in CP donors previously infected with SARS‐CoV‐2 before and after immunization. Methods and Materials: Samples were assayed from previously SARS‐CoV‐2 infected donors before ( n = 17) and after one ( n = 43) or two ( n = 71) doses of Astra‐Zeneca or Pfizer vaccinations. Ab titers against Wuhan/wild type (WT), Alpha, Beta, and Delta SARS‐CoV‐2 strains were determined by live virus microneutralization assay while titers to Omicron used a focus reduction neutralization test. Anti‐spike antibody was assayed by Elecsys anti‐SARS‐CoV‐2 quantitative spike assay (Roche). Results: Unvaccinated donors showed a geometric mean titer (GMT) of 148 against WT, 80 against Alpha but mostly failed to neutralize Beta, Delta, and Omicron strains. Contrastingly, high GMTs were observed in vaccinated donors against all SARS‐CoV‐2 strains after one vaccine dose (WT:703; Alpha:692; Beta:187; Delta:215; Omicron:434). By ROC analysis, reactivity in the Roche quantitative Elecsys spike assay of 20, 000 U/mL was highly predictive of donations with nAb titers of ≥1:640 against Delta (90% sensitivity; 97% specificity) and ≥1:320 against Omicron (89% sensitivity; 81% specificity). Discussion: Vaccination of previously infected CP donors induced high levels of broadly neutralizing antibodies against circulating antigenic variants of SARS‐CoV‐2. High titer donations could be reliably identified by automated quantitative anti‐spike antibody assay, enabling large‐scale preselection of high‐titer convalescent plasma. … (more)
- Is Part Of:
- Transfusion. Volume 62:Issue 7(2022)
- Journal:
- Transfusion
- Issue:
- Volume 62:Issue 7(2022)
- Issue Display:
- Volume 62, Issue 7 (2022)
- Year:
- 2022
- Volume:
- 62
- Issue:
- 7
- Issue Sort Value:
- 2022-0062-0007-0000
- Page Start:
- 1347
- Page End:
- 1354
- Publication Date:
- 2022-06-02
- Subjects:
- antibody neutralization -- antigenic variants -- convalescent plasma -- COVID‐19 -- Delta -- Omicron -- SARS‐CoV‐2 -- vaccination
Hematology -- Periodicals
Blood -- Transfusion -- Periodicals
Blood Group Antigens -- Periodicals
Blood Preservation -- Periodicals
Blood Transfusion -- Periodicals
615 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1537-2995 ↗
http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=trf ↗
http://www.transfusion.org ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/trf.16934 ↗
- Languages:
- English
- ISSNs:
- 0041-1132
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 9020.704000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 22396.xml